Gilboa Therapeutics

Gilboa Therapeutics is a preclinical-stage biopharmaceutical company developing novel cancer immunotherapies, with operations based across 2 corporate locations in Rehovot, Israel, and Boston, Massachusetts. The venture-backed spinoff utilizes its proprietary SolidT technology platform to engineer a patient's own T cells, aiming to target solid tumor cells while preserving surrounding healthy tissue. This core technological framework originally emerged from oncology research conducted at Tel Aviv University. The enterprise has subsequently received financial backing from the early-stage venture capital firm NFX to advance its commercialization efforts for targeted healthcare providers and patients. The organization's clinical and operational leadership team has included prominent industry executives such as former chief executive officer Barry Labinger, acting chief medical officer Jim Wooldridge, and chief operating officer Itamar Levy. Gilboa Therapeutics was officially founded in 2020 by principal investigator Yaron Carmi.

High-Level Overview

Gilboa Therapeutics is a preclinical-stage biopharmaceutical company developing SolidT, a novel engineered T cell therapy platform for cancer immunotherapy.[1][2][3] It targets solid and hematological tumors by genetically modifying patient T cells to express a high-affinity antibody receptor that activates only against high-antigen tumor cells coated with tumor-specific antibodies, sparing healthy tissue and overcoming limitations like T-cell exhaustion and toxicity seen in CAR-T therapies.[1][2][3] The company serves oncology patients and healthcare providers, addressing the challenge of effective, safe treatments for solid tumors, which have resisted traditional cell therapies.[1][5] Backed by NFX and operating at seed stage with 1-10 employees, Gilboa shows early momentum through preclinical data presented at the 2024 AACR meeting, demonstrating tumor eradication and immune memory in animal models.[1][2]

Origin Story

Founded in 2020 as a spinoff from Dr. Yaron Carmi's lab at Tel Aviv University, Gilboa Therapeutics emerged from research into advanced T cell engineering for solid tumors.[1][3] The SolidT technology originated in this academic setting, where scientists addressed CAR-T's shortcomings by creating T cells with an engineered antibody receptor for precise tumor targeting.[2][3] Key early milestones include preclinical validation in challenging animal models and a 2024 AACR presentation highlighting the platform's ability to destroy tumors while establishing immune memory against recurrence.[1] Leadership includes CEO Barry Labinger, with operations co-located in Rehovot, Israel, and Boston, USA, reflecting a blend of Israeli biotech innovation and U.S. market access.[1][3]

Core Differentiators

• Precision Targeting: SolidT T cells activate solely on high-antigen tumor cells via an engineered antibody receptor, avoiding low-expression healthy cells and reducing toxicity—unlike CAR-T, which struggles with solid tumor microenvironments.[1][2][3]
• Broad Applicability: Platform works for both solid and blood cancers using off-the-shelf tumor-specific antibodies, eliminating the need for patient-specific CAR designs per target.[1][2][5]
• Superior Preclinical Outcomes: Achieves complete tumor eradication in animal models, establishes immune memory for secondary tumors, and shows no harm to normal tissue.[1][3]
• Safety and Versatility: Overcomes T-cell exhaustion and immunosuppression; genetically engineered for high specificity and potency.[2][3]

Role in the Broader Tech Landscape

Gilboa rides the cell therapy revolution, particularly the push beyond CAR-T limitations for solid tumors, which represent 90% of cancers but lag in immunotherapy success.[1][5] Timing aligns with surging investment in next-gen immunotherapies amid clinical setbacks for first-wave CAR-T in solids, amplified by advances in antibody engineering and gene editing.[2][3] Favorable market forces include a $50B+ oncology cell therapy pipeline, regulatory tailwinds for safer platforms, and Israel's biotech hub status fueling global spinoffs.[1] Gilboa influences the ecosystem by validating academic-to-commercial translation, potentially accelerating antibody-T cell combos and drawing more VC to precision oncology.[1][2]

Quick Take & Future Outlook

Gilboa is poised for seed-to-Series A progression, with milestones like IND filings for SolidT in solid tumors likely in 2026-2027, leveraging AACR data for partnerships with big pharma seeking CAR-T alternatives.[1][2] Trends like bispecific antibodies and allogeneic cells will amplify SolidT's modularity, while AI-driven antigen discovery could expand its pipeline.[3] Its influence may grow by pioneering safer, scalable therapies, reshaping solid tumor standards and boosting Israel's role in global immuno-oncology—positioning it as a high-impact player in saving lives through patient immune systems.[1][2]